Europe Addresses Antibiotic Resistance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Europe Addresses Antibiotic Resistance


Pharmaceutical Technology Europe
Volume 22, Issue 12

R&D hurdles

Raising awareness of antibiotic resistance is aimed at preserving the effectiveness of the currently available agents, but there is an urgent need to develop a new generation of antibiotics for the future. While some of the major pharmaceutical companies, such as Pfizer, GlaxoSmithKline and Merck, have maintained some interest in antibiotic R&D, most innovative research in this field is now being carried out by smaller companies.9

During the mid- to late-1990s, many large pharmaceutical companies reduced or abandoned antibiotic R&D programmes because the market was considered too crowded and financially unrewarding.9 The experience of Lilly, who developed daptomycin, convinced some companies that their efforts would be better spent in other areas.9 Daptomycin proved to have antibacterial activity, but was not considered particularly potent compared with existing agents on the market. In addition, it was found to have a narrow therapeutic window. During trials to examine higher doses, some volunteers developed muscle damage. Since Lilly already marketed vancomycin, an immensely popular broad-spectrum antibiotic, there was limited interest in funding another risky antibiotic R&D project. Even if successful, a new antibiotic might have ended up eroding the market for vancomycin.9 As a result of commercial nervousness, Lilly shifted its emphasis to other therapeutic areas considered more financially secure.

At the end of 2009, the Swedish government commissioned a study by the European Observatory on Health Systems and Policies to look at ways to provide new R&D incentives to pharmaceutical companies to carry out antibiotic research.3 As well as confirming that antibiotic R&D was considered a financially unattractive field for companies, it revealed underlying problems that would hamper any attempts to set up new research programmes.

According to the study, apart from commercial factors, antibiotic research in the pharmaceutical industry began to tail off partly due to a feeling that bacterial infectious diseases had been "conquered." As a result, many scientists chose to pursue research in other areas, believing them to be medically under-served. Over time, this shift in emphasis left a lack of industry personnel with the scientific experience to maintain the focus on antibiotic research.3 A number of well-funded training programmes have been initiated to give European scientists the necessary training to pursue antibiotic research, but trainees will still lack hands-on experience in dealing with infectious bacterial diseases. The European Observatory on Health Systems and Policies report concluded that as well as recruiting new scientists, efforts must be made to leverage the experience of older scientists. This may even necessitate asking retired scientists to mentor the next generation of antibiotic researchers. Only then will the pharmaceutical industry have the necessary pool of scientific talent to draw upon for new antibiotic R&D projects.

The report authors supported the idea that tax incentives could stimulate new industry antibiotic research.3 They recommended incentives to be focused on the earlier stages of R&D, as they felt that any measures linked to marketing or sales would weaken efforts to preserve current antibiotics on the market. As an example, it cited the policy approach of the French government in 2008, which was designed to make the country a more attractive environment for pharmaceutical R&D. The French Finance Act featured a reduced rate of corporation tax, but also provided preferential tax measures for various activities involved in the R&D process. For example, outsourced activities, expenses related to compliance with regulatory standards and social costs for employees with the necessary R&D expertise all had the potential to qualify for tax relief.


The author says
The study also identified a lack of information over how much new antibiotic research programmes might cost, which therefore complicates efforts to develop government policies for financial incentives. Generally, clinical trials for antibiotics are considered less complex than in other therapeutic areas, as the therapeutic endpoint is clear i.e., patient recovery from infection.3 This would suggest that R&D costs for antibiotic trials are less than say, for example, an oncology programme. Future trials, however, might involve additional costs as they might need to include a significant number of subjects with resistant pathogens.3 Since industry critics believe that pharmaceutical companies already generate excessive profits, financial incentives to kickstart antibiotic research might be publicised in the media as being unnecessary. However, the conclusions regarding the financing of antibiotic R&D programmes are based on historical data.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here